Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label, Randomized Controlled Phase 3 Study of Tislelizumab Monotherapy Versus Salvage Chemotherapy in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Next Previous
X
Search
Trial Profile

A Multicenter, Open-Label, Randomized Controlled Phase 3 Study of Tislelizumab Monotherapy Versus Salvage Chemotherapy in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tislelizumab (Primary) ; Carboplatin; Cisplatin; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Gemcitabine; Ifosfamide; Mesna; Methylprednisolone; Mitoxantrone; Prednisone; Vinorelbine
  • Indications Hodgkin's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors BeiGene

    • Most Recent Events

    • 25 Feb 2021 According to a BeiGene media release, first patient has been dosed in this trial.
    • 25 Feb 2021 Status changed from not yet recruiting to recruiting, according to a BeiGene media release.
    • 30 Sep 2020 Planned initiation date changed from 17 Aug 2020 to 25 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top